These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12787055)

  • 1. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
    Dedeoglu A; Kubilus JK; Yang L; Ferrante KL; Hersch SM; Beal MF; Ferrante RJ
    J Neurochem; 2003 Jun; 85(6):1359-67. PubMed ID: 12787055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
    Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF
    J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
    Andreassen OA; Dedeoglu A; Ferrante RJ; Jenkins BG; Ferrante KL; Thomas M; Friedlich A; Browne SE; Schilling G; Borchelt DR; Hersch SM; Ross CA; Beal MF
    Neurobiol Dis; 2001 Jun; 8(3):479-91. PubMed ID: 11447996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
    Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
    Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
    Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
    J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
    Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
    J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of cystamine in a murine model of Huntington's disease.
    Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
    J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
    Ferrante RJ; Kubilus JK; Lee J; Ryu H; Beesen A; Zucker B; Smith K; Kowall NW; Ratan RR; Luthi-Carter R; Hersch SM
    J Neurosci; 2003 Oct; 23(28):9418-27. PubMed ID: 14561870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
    Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
    Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
    Cardinale A; Paldino E; Giampà C; Bernardi G; Fusco FR
    PLoS One; 2015; 10(8):e0134482. PubMed ID: 26252217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
    Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
    Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2016 Oct; 5(3):285-296. PubMed ID: 27567888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.
    Cherny RA; Ayton S; Finkelstein DI; Bush AI; McColl G; Massa SM
    J Huntingtons Dis; 2012; 1(2):211-9. PubMed ID: 25063332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
    Kao YH; Lin MS; Chen CM; Wu YR; Chen HM; Lai HL; Chern Y; Lin CJ
    Hum Mol Genet; 2017 Feb; 26(3):467-478. PubMed ID: 28069792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.
    Simmons DA; Mehta RA; Lauterborn JC; Gall CM; Lynch G
    Neurobiol Dis; 2011 Feb; 41(2):436-44. PubMed ID: 20977939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.